Acute Lung Injury - Pipeline Review, H1 2016

Published: Jun, 2016 | Pages: 114 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Acute Lung Injury - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Acute Lung Injury - Pipeline Review, H1 2016', provides an overview of the Acute Lung Injury pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Acute Lung Injury, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Acute Lung Injury and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Acute Lung Injury
- The report reviews pipeline therapeutics for Acute Lung Injury by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Acute Lung Injury therapeutics and enlists all their major and minor projects
- The report assesses Acute Lung Injury therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Acute Lung Injury

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Acute Lung Injury
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Acute Lung Injury pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 8
List of Figures 9
Introduction 10
Global Markets Direct Report Coverage 10
Acute Lung Injury Overview 11
Therapeutics Development 12
Pipeline Products for Acute Lung Injury - Overview 12
Pipeline Products for Acute Lung Injury - Comparative Analysis 13
Acute Lung Injury - Therapeutics under Development by Companies 14
Acute Lung Injury - Therapeutics under Investigation by Universities/Institutes 17
Acute Lung Injury - Pipeline Products Glance 18
Clinical Stage Products 18
Early Stage Products 19
Acute Lung Injury - Products under Development by Companies 20
Acute Lung Injury - Products under Investigation by Universities/Institutes 22
Acute Lung Injury - Companies Involved in Therapeutics Development 23
Altor BioScience Corporation 23
Apeptico Forschung und Entwicklung GmbH 24
Commence Bio, Inc. 25
CompleGen, Inc. 26
FirstString Research, Inc. 27
GlaxoSmithKline Plc 28
Histocell S.L. 29
Navigen Pharmaceuticals, Inc. 30
Noxxon Pharma AG 31
Quark Pharmaceuticals, Inc. 32
S-Evans Biosciences, Inc. 33
Silence Therapeutics Plc 34
Stemedica Cell Technologies, Inc. 35
Windtree Therapeutics, Inc. 36
Acute Lung Injury - Therapeutics Assessment 37
Assessment by Monotherapy Products 37
Assessment by Target 38
Assessment by Mechanism of Action 40
Assessment by Route of Administration 42
Assessment by Molecule Type 44
Drug Profiles 46
ALT-836 - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
Atu-111 - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
BC-1215 - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
BIO-10901 - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
CGX-1037 - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
CMB-200 - Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
Drugs to Antagonize IGF-1 Receptor for Acute Lung Injury and Pulmonary Fibrosis - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
Drugs to Inhibit Adenosine A1 Receptor for Lung Injury and Lung Inflammation - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
FAB-117-HC - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
GSK-2586881 - Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
GSK-2862277 - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
L-Citrulline - Drug Profile 58
Product Description 58
Mechanism Of Action 58
R&D Progress 58
LTI-02 - Drug Profile 59
Product Description 59
Mechanism Of Action 59
R&D Progress 59
lucinactant - Drug Profile 60
Product Description 60
Mechanism Of Action 60
R&D Progress 60
MG-53 - Drug Profile 67
Product Description 67
Mechanism Of Action 67
R&D Progress 67
Monoclonal Antibodies to Inhibit uPA for Infectious Disease and Respiratory Disorders - Drug Profile 69
Product Description 69
Mechanism Of Action 69
R&D Progress 69
Monoclonal Antibody 1 to Inhibit Aminoprocalcitonin for Sepsis, SIRS, Acute Lung Injury and Alzheimer's Disease - Drug Profile 70
Product Description 70
Mechanism Of Action 70
R&D Progress 70
Monoclonal Antibody 2 to Inhibit Aminoprocalcitonin for Sepsis, SIRS, Acute Lung Injury and Alzheimer's Disease - Drug Profile 71
Product Description 71
Mechanism Of Action 71
R&D Progress 71
Monoclonal Antibody to Inhibit Aminoprocalcitonin for Sepsis, SIRS, Acute Lung Injury and Alzheimer's Disease - Drug Profile 72
Product Description 72
Mechanism Of Action 72
R&D Progress 72
NAV-2729 - Drug Profile 73
Product Description 73
Mechanism Of Action 73
R&D Progress 73
NOXD-19 - Drug Profile 76
Product Description 76
Mechanism Of Action 76
R&D Progress 76
Oligonucleotide to Inhibit Endothelin-1 for CVS, Oncology and Respiratory Diseases - Drug Profile 77
Product Description 77
Mechanism Of Action 77
R&D Progress 77
P- BEFizumab - Drug Profile 78
Product Description 78
Mechanism Of Action 78
R&D Progress 78
Peptide to Activate PAI-1 for Acute Lung Injury - Drug Profile 79
Product Description 79
Mechanism Of Action 79
R&D Progress 79
QPLI-2 - Drug Profile 80
Product Description 80
Mechanism Of Action 80
R&D Progress 80
R-10001 - Drug Profile 81
Product Description 81
Mechanism Of Action 81
R&D Progress 81
R-107 - Drug Profile 82
Product Description 82
Mechanism Of Action 82
R&D Progress 82
R-901 - Drug Profile 83
Product Description 83
Mechanism Of Action 83
R&D Progress 83
R-911 - Drug Profile 85
Product Description 85
Mechanism Of Action 85
R&D Progress 85
Recombinant Protein for Acute Lung Injury, Sepsis and Chronic Inflammation - Drug Profile 86
Product Description 86
Mechanism Of Action 86
R&D Progress 86
Recombinant Proteins for Acute Lung Injury and Acute Respiratory Distress Syndrome - Drug Profile 87
Product Description 87
Mechanism Of Action 87
R&D Progress 87
S-1229 - Drug Profile 88
Product Description 88
Mechanism Of Action 88
R&D Progress 88
Small Molecules to Antagonize TLR4 for Acute Lung Injury and Bacterial Sepsis - Drug Profile 89
Product Description 89
Mechanism Of Action 89
R&D Progress 89
solnatide - Drug Profile 90
Product Description 90
Mechanism Of Action 90
R&D Progress 90
Stem Cell Therapy for Acute Lung Injury - Drug Profile 92
Product Description 92
Mechanism Of Action 92
R&D Progress 92
Stem Cell Therapy for Acute Lung Injury - Drug Profile 93
Product Description 93
Mechanism Of Action 93
R&D Progress 93
Stem Cell Therapy for Cardiovascular Disease, CNS Disorders, Metabolic Disorders, Respiratory Disease, Infectious Disease and Toxicology - Drug Profile 94
Product Description 94
Mechanism Of Action 94
R&D Progress 94
Stem Cell Therapy for Metabolic, Gastrointestinal and Respiratory Disorders - Drug Profile 99
Product Description 99
Mechanism Of Action 99
R&D Progress 99
Stem Cell Therapy for Osteoarthritis, Diabetes Mellitus, Acute Liver Failure and Neurodegenerative Diseases - Drug Profile 100
Product Description 100
Mechanism Of Action 100
R&D Progress 100
Synthetic Peptide for Acute Lung Injury and Acute Respiratory Distress Syndrome - Drug Profile 101
Product Description 101
Mechanism Of Action 101
R&D Progress 101
Synthetic Peptides for Respiratory Distress Syndrome and Acute Lung Injury - Drug Profile 102
Product Description 102
Mechanism Of Action 102
R&D Progress 102
TXA-302 - Drug Profile 103
Product Description 103
Mechanism Of Action 103
R&D Progress 103
Acute Lung Injury - Dormant Projects 104
Acute Lung Injury - Discontinued Products 106
Acute Lung Injury - Product Development Milestones 107
Featured News & Press Releases 107
Jul 30, 2015: Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 107
Aug 05, 2014: Silence Therapeutics Announces Publication of pre-clinical study data on use of Atu111 RNAi in sepsis 107
Oct 08, 2013: Discovery Labs Announces Notice of Allowance for a U.S. Patent Supporting the AEROSURF Development Program 108
Sep 27, 2012: Discovery Labs Initiates Research Projects With Research Institutions And US Government Agencies To Assess KL(4) Surfactant Utility In Acute Lung Injury 108
Sep 10, 2012: Silence Therapeutics' Proof of Concept Study In Preclinical Model Shows Survival Benefit With Atu111 In Combination With Antibiotics 109
Dec 19, 2011: Apeiron Biologics Announces Initiation Of Phase IIa Study In Acute Lung Injury Patients 110
May 23, 2011: Altor BioScience Receives $3m SBIR Phase II Competing Renewal Grant From NHLBI 110
Apr 20, 2011: Discovery Labs's KL4 Surfactant Aerosolization Program Data To Be Presented At Pediatric Academic Societies Annual Meeting 111
Sep 08, 2009: APEPTICO Presents Lead Product AP301 At Annual Congress Of European Respiratory Society In Vienna, Austria 111
Appendix 113
Methodology 113
Coverage 113
Secondary Research 113
Primary Research 113
Expert Panel Validation 113
Contact Us 113
Disclaimer 114

List of Tables

Number of Products under Development for Acute Lung Injury, H1 2016 12
Number of Products under Development for Acute Lung Injury - Comparative Analysis, H1 2016 13
Number of Products under Development by Companies, H1 2016 15
Number of Products under Development by Companies, H1 2016 (Contd..1) 16
Number of Products under Investigation by Universities/Institutes, H1 2016 17
Comparative Analysis by Clinical Stage Development, H1 2016 18
Comparative Analysis by Early Stage Development, H1 2016 19
Products under Development by Companies, H1 2016 20
Products under Development by Companies, H1 2016 (Contd..1) 21
Products under Investigation by Universities/Institutes, H1 2016 22
Acute Lung Injury - Pipeline by Altor BioScience Corporation, H1 2016 23
Acute Lung Injury - Pipeline by Apeptico Forschung und Entwicklung GmbH, H1 2016 24
Acute Lung Injury - Pipeline by Commence Bio, Inc., H1 2016 25
Acute Lung Injury - Pipeline by CompleGen, Inc., H1 2016 26
Acute Lung Injury - Pipeline by FirstString Research, Inc., H1 2016 27
Acute Lung Injury - Pipeline by GlaxoSmithKline Plc, H1 2016 28
Acute Lung Injury - Pipeline by Histocell S.L., H1 2016 29
Acute Lung Injury - Pipeline by Navigen Pharmaceuticals, Inc., H1 2016 30
Acute Lung Injury - Pipeline by Noxxon Pharma AG, H1 2016 31
Acute Lung Injury - Pipeline by Quark Pharmaceuticals, Inc., H1 2016 32
Acute Lung Injury - Pipeline by S-Evans Biosciences, Inc., H1 2016 33
Acute Lung Injury - Pipeline by Silence Therapeutics Plc, H1 2016 34
Acute Lung Injury - Pipeline by Stemedica Cell Technologies, Inc., H1 2016 35
Acute Lung Injury - Pipeline by Windtree Therapeutics, Inc., H1 2016 36
Assessment by Monotherapy Products, H1 2016 37
Number of Products by Stage and Target, H1 2016 39
Number of Products by Stage and Mechanism of Action, H1 2016 41
Number of Products by Stage and Route of Administration, H1 2016 43
Number of Products by Stage and Molecule Type, H1 2016 45
Acute Lung Injury - Dormant Projects, H1 2016 104
Acute Lung Injury - Dormant Projects (Contd..1), H1 2016 105
Acute Lung Injury - Discontinued Products, H1 2016 106